보도자료
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea
Copyright 2020 - BIXINK | Terms of Use | Contact
서울특별시 강남구 강남대로 292 6층 [06258]
6F, 292 Gangnam-daero, Gangnam-gu, Seoul 06258, Republic of Korea
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea